At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AUPH Aurinia Pharmaceuticals
Pre-Market Trading 01-24 07:51:24 EST
8.03
+0.30
+3.88%
High8.05Low7.67Vol1.04M
Open7.69D1 Closing7.73Amplitude4.94%
Mkt Cap1.15BTradable Cap1.06BTotal Shares143.18M
T/O8.24MT/O Rate0.79%Tradable Shares131.70M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Aurinia (AUPH) Upgraded to Buy: Here's Why
Zacks  ·  01-23 01:00
Aurinia (AUPH) Upgraded to Buy: Here's Why
Exploring Three High Growth Tech Stocks In The United States
Simply Wall St.  ·  2024-12-12
Exploring Three High Growth Tech Stocks In The United States
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
Zacks  ·  2024-12-10
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownership
Simply Wall St.  ·  2024-12-06
While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownership
We Might See A Profit From Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Soon
Simply Wall St.  ·  2024-12-03
We Might See A Profit From Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Soon
Positive Outlook for Aurinia Pharmaceuticals Boosted by Favorable Lupus Nephritis Guidelines
TIPRANKS  ·  2024-11-21
Positive Outlook for Aurinia Pharmaceuticals Boosted by Favorable Lupus Nephritis Guidelines
Aurinia Pharmaceuticals Celebrates New Lupus Nephritis Guidelines
TIPRANKS  ·  2024-11-19
Aurinia Pharmaceuticals Celebrates New Lupus Nephritis Guidelines
Aurinia Commends 2024 Updated Acr Guidelines for Screening, Treatment, and Management of Lupus Nephritis
THOMSON REUTERS  ·  2024-11-19
Aurinia Commends 2024 Updated Acr Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Business Wire  ·  2024-11-19
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Aurinia Highlights Lupus Nephritis Breakthroughs at ACR 2024
TIPRANKS  ·  2024-11-15
Aurinia Highlights Lupus Nephritis Breakthroughs at ACR 2024
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of Lupkynis® in Managing Ln at American College of Rheumatology Convergence 2024
THOMSON REUTERS  ·  2024-11-15
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of Lupkynis® in Managing Ln at American College of Rheumatology Convergence 2024
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
Business Wire  ·  2024-11-15
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
RBC Adjusts Aurinia Pharmaceuticals' Price Target to $9 From $8, Keeps Outperform Speculative Risk Rating
MT Newswires Live  ·  2024-11-11
RBC Adjusts Aurinia Pharmaceuticals' Price Target to $9 From $8, Keeps Outperform Speculative Risk Rating
Aurinia Pharmaceuticals (AUPH) Gets a Buy from RBC Capital
TIPRANKS  ·  2024-11-11
Aurinia Pharmaceuticals (AUPH) Gets a Buy from RBC Capital
Positive Outlook on Aurinia Pharmaceuticals Amid Strong Financial Performance and Strategic Cost Management
TIPRANKS  ·  2024-11-11
Positive Outlook on Aurinia Pharmaceuticals Amid Strong Financial Performance and Strategic Cost Management
Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon
seekingalpha  ·  2024-11-09
Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon
Aurinia Pharmaceuticals: Strong Q3 Performance and Promising Outlook Justify Buy Rating
TIPRANKS  ·  2024-11-08
Aurinia Pharmaceuticals: Strong Q3 Performance and Promising Outlook Justify Buy Rating
Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
GuruFocus.com  ·  2024-11-08
Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
Aurinia stock jumps 14% on Q3 earnings, restructuring announcement
seekingalpha  ·  2024-11-08
Aurinia stock jumps 14% on Q3 earnings, restructuring announcement
Aurinia Pharmaceuticals Reports Q3 Beat, Plans to Cut Workforce by 45%; Shares Rise
MT Newswires Live  ·  2024-11-07
Aurinia Pharmaceuticals Reports Q3 Beat, Plans to Cut Workforce by 45%; Shares Rise

Introduction

Company Name.
Aurinia Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Issue price:
--